Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone
Status:
RECRUITING
Trial end date:
2027-09-30
Target enrollment:
Participant gender:
Summary
This study will evaluate the use of hyperpolarized 13C MRI (HP 13C MRI) and the HP-derived 13C pyruvate-to-lactate conversion rate constant (kPL) as an early response biomarker in men with treatment-naïve, high-risk, localized or locally advanced prostate cancer receiving neoadjuvant therapy.
Phase:
PHASE2
Details
Lead Sponsor:
Ivan de Kouchkovsky, MD
Treatments:
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole abiraterone Abiraterone Acetate Glutamate Carboxypeptidase II Magnetic Resonance Spectroscopy Prednisone Pyruvic Acid